These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 21768400)

  • 1. Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant.
    Matte-Martone C; Venkatesan S; Tan HS; Athanasiadis I; Chang J; Pavisic J; Shlomchik WD
    J Immunol; 2011 Aug; 187(4):1653-63. PubMed ID: 21768400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing.
    Matte CC; Cormier J; Anderson BE; Athanasiadis I; Liu J; Emerson SG; Pear W; Shlomchik WD
    Blood; 2004 Jun; 103(11):4353-61. PubMed ID: 14982874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential requirements for myeloid leukemia IFN-γ conditioning determine graft-versus-leukemia resistance and sensitivity.
    Matte-Martone C; Liu J; Zhou M; Chikina M; Green DR; Harty JT; Shlomchik WD
    J Clin Invest; 2017 Jun; 127(7):2765-2776. PubMed ID: 28604385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.
    Young FM; Campbell A; Emo KL; Jansson J; Wang PY; Jordan CT; Mullen CA
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):622-30. PubMed ID: 18489987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
    Dash AB; Williams IR; Kutok JL; Tomasson MH; Anastasiadou E; Lindahl K; Li S; Van Etten RA; Borrow J; Housman D; Druker B; Gilliland DG
    Proc Natl Acad Sci U S A; 2002 May; 99(11):7622-7. PubMed ID: 12032333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
    Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations.
    Xu L; Lu Y; Lai J; Yu W; Zhang Y; Jin Z; Xu Y; Chen J; Zha X; Chen S; Yang L; Li Y
    Sci China Life Sci; 2015 Dec; 58(12):1276-81. PubMed ID: 26423566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.
    Matte-Martone C; Liu J; Jain D; McNiff J; Shlomchik WD
    Blood; 2008 Apr; 111(7):3884-92. PubMed ID: 18223170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.
    Lu YF; Gavrilescu LC; Betancur M; Lazarides K; Klingemann H; Van Etten RA
    Blood; 2012 Jan; 119(1):273-84. PubMed ID: 22072555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
    Doki N; Kitaura J; Uchida T; Inoue D; Kagiyama Y; Togami K; Isobe M; Ito S; Maehara A; Izawa K; Kato N; Oki T; Harada Y; Nakahara F; Harada H; Kitamura T
    Int J Hematol; 2012 Feb; 95(2):167-75. PubMed ID: 22189847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system.
    Mayotte N; Roy DC; Yao J; Kroon E; Sauvageau G
    Blood; 2002 Dec; 100(12):4177-84. PubMed ID: 12393433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease.
    Zheng H; Matte-Martone C; Li H; Anderson BE; Venketesan S; Sheng Tan H; Jain D; McNiff J; Shlomchik WD
    Blood; 2008 Feb; 111(4):2476-84. PubMed ID: 18045967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells.
    Nakahara F; Kitaura J; Uchida T; Nishida C; Togami K; Inoue D; Matsukawa T; Kagiyama Y; Enomoto Y; Kawabata KC; Chen-Yi L; Komeno Y; Izawa K; Oki T; Nagae G; Harada Y; Harada H; Otsu M; Aburatani H; Heissig B; Hattori K; Kitamura T
    Blood; 2014 Jun; 123(25):3932-42. PubMed ID: 24825862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
    Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
    Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
    Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
    J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the NUP98/HOXA9 fusion transcript in the blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia with t(7;11)(p15;p15).
    Yamamoto K; Nakamura Y; Saito K; Furusawa S
    Br J Haematol; 2000 May; 109(2):423-6. PubMed ID: 10848835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia.
    Miyazaki K; Yamasaki N; Oda H; Kuwata T; Kanno Y; Miyazaki M; Komeno Y; Kitaura J; Honda Z; Warming S; Jenkins NA; Copeland NG; Kitamura T; Nakamura T; Honda H
    Blood; 2009 May; 113(19):4702-10. PubMed ID: 19234145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
    J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression.
    Mumprecht S; Schürch C; Schwaller J; Solenthaler M; Ochsenbein AF
    Blood; 2009 Aug; 114(8):1528-36. PubMed ID: 19420358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haploinsufficiency and acquired loss of Bcl11b and H2AX induces blast crisis of chronic myelogenous leukemia in a transgenic mouse model.
    Nagamachi A; Yamasaki N; Miyazaki K; Oda H; Miyazaki M; Honda Z; Kominami R; Inaba T; Honda H
    Cancer Sci; 2009 Jul; 100(7):1219-26. PubMed ID: 19432895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.